Literature DB >> 34270351

ONBOARD: A Feasibility Study of a Telehealth-Based Continuous Glucose Monitoring Adoption Intervention for Adults with Type 1 Diabetes.

Molly L Tanenbaum1,2, Jessica Ngo1, Sarah J Hanes1, Marina Basina2,3, Bruce A Buckingham1,2, Danielle Hessler4, David M Maahs1,2, Shelagh Mulvaney5,6, Korey K Hood1,2.   

Abstract

Background: Continuous glucose monitoring (CGM) can improve glycemic control for adults with type 1 diabetes (T1D) but certain barriers interfere with consistent use including cost, data overload, alarm fatigue, physical discomfort, and unwanted social attention. This pilot study aimed to examine feasibility and acceptability of a behavioral intervention, ONBOARD (Overcoming Barriers and Obstacles to Adopting Diabetes Devices) to support adults with T1D in optimizing CGM use.
Methods: Adults (18-50 years) with T1D in their first year of CGM use were invited to participate in a tailored, multicomponent telehealth-based intervention delivered over four 60-min sessions every 2-3 weeks. Participants completed surveys (demographics; diabetes distress, Diabetes Distress Scale for adults with type 1 diabetes; satisfaction with program) and provided CGM data at baseline and postintervention (3 months). Data were analyzed using paired t-tests and Wilcoxon signed-rank tests.
Results: Twenty-two participants (age = 30.95 ± 8.32 years; 59% women; 91% non-Hispanic; 86% White, 5% Black, 9% other; 73% pump users) completed the study. ONBOARD demonstrated acceptability and a high rate of retention. Moderate effect sizes were found for reductions in diabetes distress (P = 0.01, r = -0.37) and increases in daytime spent in target range (70-180 mg/dL: P = 0.03, r = -0.35). There were no significant increases in hypoglycemia. Conclusions: Findings show preliminary evidence of feasibility, acceptability, and efficacy of ONBOARD for supporting adults with T1D in optimizing CGM use while alleviating diabetes distress. Further research is needed to examine ONBOARD in a larger sample over a longer period.

Entities:  

Keywords:  Adults; Continuous glucose monitoring; Health care delivery; Psychosocial aspects; Telehealth; Type 1 diabetes

Mesh:

Substances:

Year:  2021        PMID: 34270351      PMCID: PMC8819504          DOI: 10.1089/dia.2021.0198

Source DB:  PubMed          Journal:  Diabetes Technol Ther        ISSN: 1520-9156            Impact factor:   6.118


  35 in total

1.  The impact of a structured education and treatment programme (FLASH) for people with diabetes using a flash sensor-based glucose monitoring system: Results of a randomized controlled trial.

Authors:  Norbert Hermanns; Dominic Ehrmann; Melanie Schipfer; Jens Kröger; Thomas Haak; Bernhard Kulzer
Journal:  Diabetes Res Clin Pract       Date:  2019-03-04       Impact factor: 5.602

2.  Uninterrupted continuous glucose monitoring access is associated with a decrease in HbA1c in youth with type 1 diabetes and public insurance.

Authors:  Ananta Addala; David M Maahs; David Scheinker; Solana Chertow; Brianna Leverenz; Priya Prahalad
Journal:  Pediatr Diabetes       Date:  2020-08-10       Impact factor: 4.866

3.  Trust in hybrid closed loop among people with diabetes: Perspectives of experienced system users.

Authors:  Molly L Tanenbaum; Esti Iturralde; Sarah J Hanes; Sakinah C Suttiratana; Jodie M Ambrosino; Trang T Ly; David M Maahs; Diana Naranjo; Natalie Walders-Abramson; Stuart A Weinzimer; Bruce A Buckingham; Korey K Hood
Journal:  J Health Psychol       Date:  2017-07-12

4.  Sustained Continuous Glucose Monitor Use in Low-Income Youth with Type 1 Diabetes Following Insurance Coverage Supports Expansion of Continuous Glucose Monitor Coverage for All.

Authors:  Priya Prahalad; Ananta Addala; Bruce A Buckingham; Darrell M Wilson; David M Maahs
Journal:  Diabetes Technol Ther       Date:  2018-07-18       Impact factor: 6.118

5.  State of Type 1 Diabetes Management and Outcomes from the T1D Exchange in 2016-2018.

Authors:  Nicole C Foster; Roy W Beck; Kellee M Miller; Mark A Clements; Michael R Rickels; Linda A DiMeglio; David M Maahs; William V Tamborlane; Richard Bergenstal; Elizabeth Smith; Beth A Olson; Satish K Garg
Journal:  Diabetes Technol Ther       Date:  2019-01-18       Impact factor: 6.118

6.  A multicenter randomized controlled trial of motivational interviewing in teenagers with diabetes.

Authors:  Sue J Channon; Michelle V Huws-Thomas; Stephen Rollnick; Kerenza Hood; Rebecca L Cannings-John; Carol Rogers; John W Gregory
Journal:  Diabetes Care       Date:  2007-03-10       Impact factor: 19.112

7.  The Impact of Continuous Glucose Monitoring on Markers of Quality of Life in Adults With Type 1 Diabetes: Further Findings From the DIAMOND Randomized Clinical Trial.

Authors:  William H Polonsky; Danielle Hessler; Katrina J Ruedy; Roy W Beck
Journal:  Diabetes Care       Date:  2017-04-07       Impact factor: 19.112

8.  Telehealth as a Bright Spot of the COVID-19 Pandemic: Recommendations From the Virtual Frontlines ("Frontweb").

Authors:  J Nwando Olayiwola; Candy Magaña; Ashley Harmon; Shalina Nair; Erica Esposito; Christine Harsh; L Arick Forrest; Randy Wexler
Journal:  JMIR Public Health Surveill       Date:  2020-06-25

9.  Pilot Study of a Web-Delivered Multicomponent Intervention for Rural Teens with Poorly Controlled Type 1 Diabetes.

Authors:  Amy Hughes Lansing; Catherine Stanger; Alan Budney; Ann S Christiano; Samuel J Casella
Journal:  J Diabetes Res       Date:  2016-08-17       Impact factor: 4.011

View more
  2 in total

1.  Help when you need it: Perspectives of adults with T1D on the support and training they would have wanted when starting CGM.

Authors:  Molly L Tanenbaum; Laurel H Messer; Christine A Wu; Marina Basina; Bruce A Buckingham; Danielle Hessler; Shelagh A Mulvaney; David M Maahs; Korey K Hood
Journal:  Diabetes Res Clin Pract       Date:  2021-09-14       Impact factor: 8.180

Review 2.  Barriers and Facilitators to Diabetes Device Adoption for People with Type 1 Diabetes.

Authors:  Molly L Tanenbaum; Persis V Commissariat
Journal:  Curr Diab Rep       Date:  2022-05-06       Impact factor: 5.430

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.